Nexus Pharmaceuticals, Inc. v. Nephron SC, Inc.
Infringement action filed 14 Jan 2022 in the United States District Court for the District of South Carolina and closed 9 Jan 2023, with US11090278B2 asserted. Recorded basis of termination: voluntary dismissal.
Case record
- Patent involved
- US11090278B2
- Application no.
- US16/876020
- Case no.
- 3:22-cv-00137
- Verdict cause
- Infringement action
- Court
- D.S.C.
- Court level
- District Court
- Case region
- South Carolina
- Chief judge
- Mary G. Lewis
- Trial level
- First instance
- Filed – Closed
- 14 Jan 2022 – 9 Jan 2023
- Duration
- 360 days
- Basis of termination
- Voluntary dismissal
- Products & marks
- Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
- Validity challenges
- None recorded
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
The present disclosure provides compositions comprising ephedrine sulfate ready for immediate use in a clinical setting, and methods of making and using same.
- Legal status
- Active
- Granted
- 17 Aug 2021
- Earliest priority
- 16 May 2019
- Est. expiry
- 16 May 2040
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- AHMED, SHAHID
- Classification
- A61K31/135A61K31/137A61K9/00
- Prosecution counsel
- Incubate IP
- Examiner
- KANTAMNENI, SHOBHA
Parties of record
Nexus Pharmaceuticals, Inc.
- Core tech
- A61K31/135A61K31/137A61K9/00
- Counsel
- Amy Elizabeth Allen Hinson · Tasneem Dharamsi · Timothy David St Clair
- Firm
- Parker Poe Adams & Bernstein LLP (Gre)
Nephron SC, Inc.
- Core tech
- Not recorded
- Counsel
- Nikole Setzler Mergo · Rhett Douglas Ricard · Seth Lee Hudson
- Firm
- Nexsen Pruet LLC, Nexsen Pruet LLC (Cola), Nexsen Pruet LLC (NC)
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Amy Elizabeth Allen Hinson | Nexus Pharmaceuticals, Inc. | Plaintiff |
| Tasneem Dharamsi | Nexus Pharmaceuticals, Inc. | Plaintiff |
| Timothy David St Clair | Nexus Pharmaceuticals, Inc. | Plaintiff |
| Nikole Setzler Mergo | Nephron SC, Inc. | Defendant |
| Rhett Douglas Ricard | Nephron SC, Inc. | Defendant |
| Seth Lee Hudson | Nephron SC, Inc. | Defendant |
Basis of termination
From the record · verbatim“Pursuant to Rule 41(a)(1)(A)(ii), Fed. R. Civ. P., Plaintiff Nexus Pharmaceuticals, Inc. and Defendant Nephron SC, Inc., hereby stipulate to the voluntary dismissal without prejudice of all claims that have been asserted by each party in this action. Each party shall bear its own costs and attorneys’ fees. WE SO STIPULATE:”
Case 3:22-cv-00137 · D.S.C. · closed 9 January 2023
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 3:22-cv-00137?
3:22-cv-00137 is a patent infringement action brought by Nexus Pharmaceuticals, Inc. against Nephron SC, Inc., filed on 14 Jan 2022 in the United States District Court for the District of South Carolina. The case closed on 9 January 2023.
Which patent was asserted in 3:22-cv-00137?
US11090278B2 (“Compositions comprising ephedrine or an ephedrine salt and methods of making and using same”), assigned to NEXUS PHARMACEUTICALS, LLC, currently active. The record also lists Compositions comprising ephedrine or an ephedrine salt and methods of making and using same.
How was case 3:22-cv-00137 terminated?
The recorded basis of termination is voluntary dismissal. The termination text reads: “Pursuant to Rule 41(a)(1)(A)(ii), Fed. R. Civ. P., Plaintiff Nexus Pharmaceuticals, Inc. and Defendant Nephron SC, Inc., hereby stipulate to the voluntary dismissal without prejudice of all claims that have been asserted by each party in this action. Each party shall bear its own costs and attorneys’ fees. WE SO STIPULATE:”
What does dismissal without prejudice mean?
A dismissal without prejudice ends this action but leaves the claims alive — the plaintiff may file them again later, subject to the limitation period.
How long did case 3:22-cv-00137 take?
360 calendar days, from filing on 14 Jan 2022 to closure on 9 January 2023.
Who were the attorneys and the judge in 3:22-cv-00137?
Chief Judge Mary G. Lewis presided. Amy Elizabeth Allen Hinson, Tasneem Dharamsi and Timothy David St Clair are recorded as counsel for plaintiff Nexus Pharmaceuticals. Nikole Setzler Mergo, Rhett Douglas Ricard and Seth Lee Hudson appear for defendant Nephron SC.
Disclaimer. This page reproduces publicly available court docket data for case 3:22-cv-00137 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.